Publications

Clinical Trials:

Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study.

Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.

Phase 2 randomized flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.


Very high-dose methotrexate (33.6 g/m2) as CNS preventive therapy for childhood acute lymphoblastic leukemia: Results of National Cancer Institute/Children’s Cancer Group trials CCG-191P, CCG-134P, and CCG-144P.

Cognitive/Neurobehavioral Functioning:

Neurobehavioral profiles in individuals with Hyperimmunoglobulin E Syndrome (HIES) and brain white matter hyperintensities.
Neurodevelopment of children under 3 years of age with Smith-Magenis syndrome.

Neuropsychological testing and biomarkers in the management of brain metastases.

Detection and characterization of neurotoxicity in cancer patients using proton MR spectroscopy.

Cognitive functioning in school-aged children with vertically acquired HIV infection being treated with highly active antiretroviral therapy (HAART).

Social-Emotional Functioning/Quality of Life:

Attitudes about internet support groups among adolescents and young adults with neurofibromatosis type 1 and their parents.

Patient-reported outcomes in neurofibromatosis and schwannomatosis clinical trials.

Family functioning and coping styles in families of children with cancer and HIV disease.

Social-emotional functioning of children and adolescents with neurofibromatosis type 1 and plexiform neurofibromas: relationships with cognitive, disease, and environmental variables.

Stressful life events and their relationship to psychological and medical functioning in children and adolescents with HIV infection.
Medication Adherence:

**Pediatric psychologist use of adherence assessments and interventions.**

**A comparison of adherence assessment methods utilized in the United States: perspectives of researchers, HIV-infected children, and their caregivers.**

**Diagnosis disclosure, medication hiding, and medical functioning among perinatally infected, HIV-positive children and adolescents.**